Dear AbbyJust read a quip from what Abby Cohen said tonight:
"To the extent that the market is now lower, we think that there's a higher price appreciation likely from current levels.'' Cohen
said companies in the financial services, pharmaceuticals and global cyclical sectors offer good potential buys."
I would like to consider myself to be a semi-educated investor, but this I am unsure of. Would FAS be considered a pharmaceutical company because of the product that it supplies or would it be considered more of a biotech company? I know it makes little difference to us long shareholders but it could attract or detract new investors in the wake of this market turmoil based on how it is perceived.
Your opinions?